Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17504126 | 0.94 | RAB9A (0.49) | RAB9ATP53MAPTMEN1KMT2A | |
| SCHEMBL17504146 | 0.91 | RAB9A (0.57) | RAB9ATP53MAPTMEN1KMT2A | |
| SCHEMBL17504175 | 0.91 | TP53 (0.51) | RAB9ATP53MAPTMEN1KMT2A | |
| SCHEMBL17504193 | 0.88 | RAB9A (0.52) | RAB9ATP53MAPTMEN1KMT2A | |
| SCHEMBL17504178 | 0.87 | TP53 (0.61) | RAB9ATP53MAPTMEN1KMT2A | |
| SCHEMBL17504225 | 0.87 | TP53 (0.61) | RAB9ATP53MAPTMEN1KMT2A | |
| SCHEMBL17504118 | 0.86 | RAB9A (0.53) | RAB9ATP53MAPTMEN1KMT2A | |
| SCHEMBL17504162 | 0.86 | RAB9A (0.53) | RAB9ATP53MAPTMEN1KMT2A | |
| SCHEMBL17504187 | 0.86 | RAB9A (0.53) | RAB9ATP53MAPTMEN1KMT2A | |
| SCHEMBL17504192 | 0.86 | TP53 (0.52) | RAB9ATP53MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180319-B1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-10-03 | — | — | EP | claimed |
| US-9902701-B2 | Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-02-27 | — | — | US | claimed |
| EP-3180319-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-06-21 | — | — | EP | claimed |
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-06-08 | — | — | US | claimed |
| WO-2016023877-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-18 | — | — | WO | claimed |
| EP-3180319-B1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-10-03 | — | — | EP | disclosed |
| US-9902701-B2 | Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902701-B2 | Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902701-B2 | Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3180319-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-06-21 | — | — | EP | disclosed |
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| WO-2016023877-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023877-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP3A43, CYP4B1 | RAB9A 3092/4885TP53 1340/4885MAPT 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.